Merck Reports Phase 3 KEYNOTE-006 Results for Keytruda in Advanced Melanoma

Merck today announced results from the Phase 3 KEYNOTE-006 trial evaluating Keytruda (pembrolizumab) versus ipilimumab in patients with advanced melanoma. The trial met its primary endpoints, demonstrating significant improvements in overall survival and progression-free survival with Keytruda. These results led to FDA approval of Keytruda for advanced melanoma.